Clinical Trials Browser

Phase 1/2 × OTHER × ensartinib × Clear all

NCT07354061 2026-01-21

TD-ENSEMBLE

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT02898116 2022-10-10

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Phase 1/2 Completed

2 enrolled 8 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung